vs
Shimmick Corp（SHIM）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Shimmick Corp的季度营收约是再鼎医药的1.1倍（$141.9M vs $127.1M），再鼎医药自由现金流更多（$-26.7M vs $-28.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -10.1%）
Shimmick Corp是一家总部位于美国的重型民用建筑企业，专注于水处理设施、交通系统、大坝工程、环境修复等关键公共基础设施的建造与升级，主要服务北美各级政府客户，承接各类复杂大型建筑项目。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
SHIM vs ZLAB — 直观对比
营收规模更大
SHIM
是对方的1.1倍
$127.1M
自由现金流更多
ZLAB
多$2.0M
$-28.7M
两年增速更快
ZLAB
近两年复合增速
-10.1%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $141.9M | $127.1M |
| 净利润 | $-4.4M | — |
| 毛利率 | 7.6% | 51.0% |
| 营业利润率 | -2.2% | -54.6% |
| 净利率 | -3.1% | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.12 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SHIMZLAB
| Q4 25 | $141.9M | $127.1M | ||
| Q3 25 | $128.4M | $115.4M | ||
| Q2 25 | $122.1M | $109.1M | ||
| Q1 25 | $103.6M | $105.7M | ||
| Q4 24 | — | $108.5M | ||
| Q3 24 | $166.0M | $101.8M | ||
| Q2 24 | $90.6M | $100.1M | ||
| Q1 24 | $120.0M | $87.1M |
净利润SHIMZLAB
| Q4 25 | $-4.4M | — | ||
| Q3 25 | $-8.5M | $-36.0M | ||
| Q2 25 | $-9.8M | $-40.7M | ||
| Q1 25 | $-38.5M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.6M | $-41.7M | ||
| Q2 24 | $-51.4M | $-80.3M | ||
| Q1 24 | $-33.3M | $-53.5M |
毛利率SHIMZLAB
| Q4 25 | 7.6% | 51.0% | ||
| Q3 25 | 6.3% | 59.5% | ||
| Q2 25 | 3.8% | 60.6% | ||
| Q1 25 | -20.1% | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | 7.3% | 64.1% | ||
| Q2 24 | -34.4% | 64.9% | ||
| Q1 24 | -13.2% | 61.4% |
营业利润率SHIMZLAB
| Q4 25 | -2.2% | -54.6% | ||
| Q3 25 | -5.5% | -42.3% | ||
| Q2 25 | -7.3% | -50.3% | ||
| Q1 25 | -39.3% | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | 0.7% | -66.6% | ||
| Q2 24 | -53.0% | -76.0% | ||
| Q1 24 | -26.5% | -80.7% |
净利率SHIMZLAB
| Q4 25 | -3.1% | — | ||
| Q3 25 | -6.6% | -31.2% | ||
| Q2 25 | -8.0% | -37.3% | ||
| Q1 25 | -37.1% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.9% | -40.9% | ||
| Q2 24 | -56.7% | -80.2% | ||
| Q1 24 | -27.8% | -61.4% |
每股收益（稀释后）SHIMZLAB
| Q4 25 | $-0.12 | $-0.05 | ||
| Q3 25 | $-0.25 | $-0.03 | ||
| Q2 25 | $-0.28 | $-0.04 | ||
| Q1 25 | $-0.92 | $-0.04 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | $-0.05 | $-0.04 | ||
| Q2 24 | $-1.83 | $-0.08 | ||
| Q1 24 | $-1.30 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $17.6M | $689.6M |
| 总债务越低越好 | $57.5M | — |
| 股东权益账面价值 | $-52.7M | $715.5M |
| 总资产 | $218.5M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资SHIMZLAB
| Q4 25 | $17.6M | $689.6M | ||
| Q3 25 | $21.4M | $717.2M | ||
| Q2 25 | $16.3M | $732.2M | ||
| Q1 25 | $33.7M | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | $26.0M | $616.1M | ||
| Q2 24 | $22.4M | $630.0M | ||
| Q1 24 | $27.3M | $650.8M |
总债务SHIMZLAB
| Q4 25 | $57.5M | — | ||
| Q3 25 | $36.4M | — | ||
| Q2 25 | $31.4M | — | ||
| Q1 25 | $9.5M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $39.9M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $31.5M | — |
股东权益SHIMZLAB
| Q4 25 | $-52.7M | $715.5M | ||
| Q3 25 | $-49.5M | $759.9M | ||
| Q2 25 | $-42.6M | $791.7M | ||
| Q1 25 | $-34.7M | $810.8M | ||
| Q4 24 | — | $840.9M | ||
| Q3 24 | $973.0K | $667.7M | ||
| Q2 24 | $436.0K | $704.2M | ||
| Q1 24 | $38.1M | $762.2M |
总资产SHIMZLAB
| Q4 25 | $218.5M | $1.2B | ||
| Q3 25 | $203.0M | $1.2B | ||
| Q2 25 | $227.7M | $1.2B | ||
| Q1 25 | $233.9M | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $346.7M | $985.3M | ||
| Q2 24 | $344.5M | $987.4M | ||
| Q1 24 | $378.0M | $988.4M |
负债/权益比SHIMZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 41.01× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.83× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-23.7M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-28.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | -20.2% | -21.0% |
| 资本支出强度资本支出/营收 | 3.5% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-27.2M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流SHIMZLAB
| Q4 25 | $-23.7M | $-26.0M | ||
| Q3 25 | $-3.8M | $-32.0M | ||
| Q2 25 | $-38.2M | $-31.0M | ||
| Q1 25 | $44.9M | $-61.7M | ||
| Q4 24 | — | $-55.8M | ||
| Q3 24 | $12.7M | $-26.8M | ||
| Q2 24 | $-43.9M | $-42.2M | ||
| Q1 24 | $-35.0M | $-90.1M |
自由现金流SHIMZLAB
| Q4 25 | $-28.7M | $-26.7M | ||
| Q3 25 | $-4.2M | $-35.0M | ||
| Q2 25 | $-38.7M | $-33.9M | ||
| Q1 25 | $44.4M | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | $10.3M | $-28.2M | ||
| Q2 24 | $-46.8M | $-42.9M | ||
| Q1 24 | $-39.6M | $-91.1M |
自由现金流率SHIMZLAB
| Q4 25 | -20.2% | -21.0% | ||
| Q3 25 | -3.2% | -30.4% | ||
| Q2 25 | -31.7% | -31.1% | ||
| Q1 25 | 42.9% | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | 6.2% | -27.7% | ||
| Q2 24 | -51.7% | -42.9% | ||
| Q1 24 | -33.0% | -104.5% |
资本支出强度SHIMZLAB
| Q4 25 | 3.5% | 0.5% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.4% | 2.6% | ||
| Q1 25 | 0.5% | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | 1.4% | 1.3% | ||
| Q2 24 | 3.3% | 0.7% | ||
| Q1 24 | 3.8% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SHIM
| Shimmick Projects | $106.8M | 75% |
| Non Core Projects | $35.1M | 25% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
